Test Price
2,800 AED✅ Home Collection Available
PRG4 Gene Sequencing (CACP Syndrome) in Dubai, UAE | 2,800 AED
Executive Summary & Core Metrics
- ✓ Diagnostic Accuracy: 99.9% sensitivity for coding region variants via targeted NGS with Sanger confirmation, performed in an ISO‑certified reference laboratory.
- ✓ VIP Mobile Phlebotomy: Temperature‑controlled cold‑chain home collection available daily from 8 AM to 11 PM – no hospital visit required.
- ✓ Clinical Guidance: Post‑test tele‑consultation with a Consultant Medical Geneticist to interpret results and coordinate multidisciplinary care.
- ✓ Insurance Verification: Direct WhatsApp support at +971 54 548 8731 for benefit confirmation and cash‑pay options.
Test Overview & Methodology
The PRG4 Gene Genetic Test detects pathogenic variants in the lubricin (PRG4) gene responsible for Camptodactyly‑Arthropathy‑Coxa Vara‑Pericarditis (CACP) syndrome. This advanced next‑generation sequencing (NGS) assay provides definitive molecular confirmation for affected individuals and clarifies recurrence risks for families. The test covers 100% of coding exons and includes deep intronic splice‑site analysis, with all clinically relevant variants confirmed by Sanger sequencing.
| Feature | Our Test (PRG4 NGS) | Closest Alternative (WES/WGS) |
|---|---|---|
| Precision | 100% coding region coverage with deep intronic splice site analysis | May miss deep intronic variants or require re‑analysis |
| Methodology | Targeted NGS with Sanger confirmation of all variants | Whole exome sequencing (fragmented coverage) |
| Turnaround Time | 3–4 Weeks | 6–12 Weeks |
| Cost in UAE | 2,800 AED (focused single‑gene) | 4,500–6,500 AED |
Physician Insight & Safety Protocols
“This PRG4 sequencing test offers a high level of diagnostic certainty for CACP syndrome, but results must always be correlated with clinical findings and family history. A negative result does not exclude the diagnosis, and ongoing specialist follow‑up with a geneticist and rheumatologist is strongly advised. Please discuss the implications with your healthcare provider before making any treatment decisions.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID 9294403
Clinical Advisory
Do not discontinue prescribed medication without consulting your doctor. Any change in therapy must be guided by a qualified physician in light of the genetic result and your overall clinical status.
Exclusion Criteria & Safety Flags
- Exclusion Criteria: Inability to provide informed consent; presence of a severe bleeding disorder (e.g., hemophilia) that contraindicates venipuncture; absence of a clear clinical indication for PRG4 testing (e.g., isolated mild camptodactyly without joint effusion, coxa vara, or pericarditis). All testing is performed in accordance with UAE Federal Decree‑Law No. 4 of 2016 on Medical Liability, and parental/guardian consent is required for minors under 18 years.
- ER Red Flags (Seek Emergency Care Independent of Test): Sudden crushing chest pain, signs of cardiac tamponade, acute joint swelling with fever, inability to bear weight, or severe hip pain with restricted movement. Genetic testing does not replace urgent medical evaluation.
Patient FAQ & Clinical Guidance
1. Who should consider the PRG4 gene test for CACP syndrome?
Snippet‑ready answer: Individuals with early‑onset joint contractures, non‑inflammatory arthropathy, coxa vara, and recurrent pericarditis should consider this test to confirm CACP syndrome and guide management. It is also recommended for family members of a known carrier to clarify recurrence risks.
2. What sample is needed and how is the collection performed?
Snippet‑ready answer: A single blood sample (2–5 mL in EDTA), extracted DNA, or a dried blood spot on an FTA card is acceptable. Collection can be performed at home via our VIP Mobile Phlebotomy service, which uses temperature‑controlled cold‑chain transport to the laboratory. Appointments are available daily from 8 AM to 11 PM.
3. How reliable is PRG4 NGS testing and what does a negative result mean?
Snippet‑ready answer: With 99.9% diagnostic sensitivity for coding region variants, this targeted NGS test is highly reliable. A negative result significantly reduces the likelihood of CACP syndrome but does not completely exclude it, especially if deep intronic or regulatory variants are suspected. Clinical and radiological correlation remains essential.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License No. 1143 and complies with all applicable UAE federal laws. Patient data is protected in accordance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Our laboratory holds ISO 9001:2015 certification (Cert. No. INT/EGQ/2509DA/3139) and follows stringent quality standards for genetic testing.
Clinical & Logistical Metadata
| Test Name | PRG4 Gene Sequencing (CACP Syndrome) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral blood (2–5 mL EDTA), extracted DNA, or dried blood spot (FTA card) |
| Methodology Used | Targeted Next‑Generation Sequencing (NGS) with Sanger confirmation |
| ICD‑10‑CM Code | Q87.8 (Other specified congenital malformation syndromes) |
| LOINC Code | 103438-9 (PRG4 gene mutational analysis) |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians